胃肠胰神经内分泌肿瘤患者接受[177Lu]Lu-DOTATATE治疗的吸收剂量-效应关系:向个体化医疗迈进一步
该研究纳入2016至2022年接受[177Lu]Lu-DOTATATE治疗的胃肠胰神经内分泌肿瘤患者,基于系列治疗后SPECT/CT进行剂量学分析。肿瘤吸收剂量与治疗结束3个月时肿瘤体积变化显著相关(P < 0.001),且为生存的显著预后因素;脾或骨髓吸收剂量与淋巴细胞或血小板浓度下降相关。结论认为肿瘤和健康器官剂量学可预测生存和毒性,从而影响临床管理。
要点
- 肿瘤吸收剂量与治疗结束3个月时肿瘤体积变化显著相关(P < 0.001),并为生存的显著预后因素。
- 脾或骨髓吸收剂量与淋巴细胞或血小板浓度下降相关,肾脏平均吸收剂量与研究期间肾毒性无相关性。
- 肿瘤中位总吸收剂量为94.4 Gy,且肿瘤吸收剂量在周期之间显著下降。
核心结论
- 在接受[177Lu]Lu-DOTATATE治疗的胃肠胰神经内分泌肿瘤患者中,肿瘤和健康器官剂量学可预测生存和毒性,从而影响临床管理。
研究设计与样本
- 纳入2016至2022年间接受[177Lu]Lu-DOTATATE治疗并进行了剂量学分析的胃肠胰神经内分泌肿瘤患者,共完成35项剂量学研究。
- 基于系列治疗后SPECT/CT,使用PLANET Dose和局部能量沉积法计算健康器官(肝脏、肾脏、骨髓和脾脏)及肿瘤的吸收剂量。
- 每个部位最多选取5个病灶,在基线和治疗结束3个月后采集的图像上进行测量,测量时对生长抑素受体显像摄取设盲。
- 定期监测实验室参数以评估毒性,从患者健康记录中收集包括至死亡或进展时间在内的临床数据。
- 使用回归模型研究器官吸收剂量与毒性之间以及病灶吸收剂量与肿瘤体积变化之间的相关性。
主要发现
- 患者肿瘤多为2级(77%),转移部位包括肝脏(89%)、淋巴结(77%)和骨(34%),共分析146个病灶,每例患者1-9个病灶,以肝转移(65%)和淋巴结(25%)为主。
- 肿瘤中位总吸收剂量为94.4 Gy,且肿瘤吸收剂量在周期之间显著下降。
- 肿瘤吸收剂量与治疗结束3个月时肿瘤体积变化显著相关(P < 0.001),且为生存的显著预后因素。
- 毒性分析显示淋巴细胞或血小板浓度等血液学参数下降与脾或骨髓吸收剂量相关。
- 研究期间肾脏平均吸收剂量与肾毒性无相关性。
关键数值与推荐
- 肿瘤吸收剂量与治疗结束3个月时肿瘤体积变化显著相关,P < 0.001。
- 肿瘤中位总吸收剂量为94.4 Gy。
- 患者肿瘤分级以2级为主(77%),转移部位肝脏89%、淋巴结77%、骨34%。
- 共分析146个病灶,每例患者1-9个病灶,肝转移占65%、淋巴结占25%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[177Lu]Lu-DOTATATE has been approved for progressive and inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that overexpress somatostatin receptors. The absorbed doses by limiting organs and tumors can be quantified by serial postinfusion scintigraphy measurements of the γ-emissions from 177Lu. The objective of this work was to explore how postinfusion [177Lu]Lu-DOTATATE dosimetry could influence clinical management by predicting treatment efficacy (tumor shrinkage and survival) and toxicity. Methods: Patients with GEP-NETs treated with [177Lu]Lu-DOTATATE between 2016 and 2022 and who underwent dosimetry were included. Absorbed doses were calculated for healthy organs (liver, kidneys, bone marrow, and spleen) and tumors using PLANET Dose and the local energy deposition method based on serial posttreatment SPECT/CT. Up to 5 lesions per site were selected and measured on images collected at baseline and 3 mo after treatment end (measurement masked to the somatostatin receptor imaging uptake). For toxicity assessment, laboratory parameters were regularly monitored. Clinical data, including time to death or progression, were collected from the patients' health records. Correlations between absorbed doses by organs and toxicity and between absorbed doses by lesions and tumor volume variation were studied using regression models. Results: In total, 35 dosimetric studies were performed in patients with mostly grade 2 (77%) tumors and metastases in liver (89%), lymph nodes (77%), and bone (34%), and 146 lesions were analyzed: 1-9 lesions per patient, mostly liver metastases (65%) and lymph nodes (25%). The median total absorbed dose by tumors was 94.4 Gy. The absorbed doses by tumors significantly decreased between cycles. The absorbed dose by tumors was significantly associated with tumor volume variation (P < 0.001) 3 mo after treatment end, and it was a significant prognostic factor for survival. Toxicity analysis showed a correlation between the decrease of hematologic parameters such as lymphocytes or platelet concentrations and the absorbed doses by the spleen or bone marrow. The mean absorbed dose by the kidneys was not correlated with nephrotoxicity during the studied period. Conclusion: In patients treated with [177Lu]Lu-DOTATATE for GEP-NETs, tumor and healthy organ dosimetry can predict survival and toxicities, thus influencing clinical management.
引用
- Hebert K, Santoro L, Monnier M, et al. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. J Nucl Med. 2024. PMID: 38637144. doi:10.2967/jnumed.123.267023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。